Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Genetische risicofactoren voor epilepsie ontdekt
sep 2023 | Epilepsie